<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>                  The clinical efficacy and safety of SELZENTRY are derived from analyses of data from 3 trials in adult subjects infected with CCR5-tropic HIV-1: A4001027 and A4001028 in antiretroviral treatment-experienced adult subjects and A4001026 in treatment-naive subjects. These trials were supported by a 48-week trial in antiretroviral treatment-experienced adult subjects infected with dual/mixed-tropic HIV-1, A4001029.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Trials in CCR5-Tropic, Treatment-Experienced Subjects<BR>                     <BR>                        Trials A4001027 and A4001028 were double-blind, randomized, placebo-controlled, multicenter trials in subjects infected with CCR5-tropic HIV-1. Subjects were required to have an HIV-1 RNA of greater than 5,000 copies/mL despite at least 6 months of prior therapy with at least 1 agent from 3 of the 4 antiretroviral drug classes (≥1 NRTI, ≥1 NNRTI, ≥2 PIs, and/or enfuvirtide) or documented resistance to at least 1 member of each class. All subjects received an optimized background regimen consisting of 3 to 6 antiretroviral agents (excluding low-dose ritonavir) selected on the basis of the subject’s prior treatment history and baseline genotypic and phenotypic viral resistance measurements. In addition to the optimized background regimen, subjects were then randomized in a 2:2:1 ratio to SELZENTRY 300 mg once daily, SELZENTRY 300 mg twice daily, or placebo. Doses were adjusted based on background therapy as described in Dosing and Administration, Table 1.<BR>                        In the pooled analysis for A4001027 and A4001028, the demographics and baseline characteristics of the treatment groups were comparable (Table 12). Of the 1,043 subjects with a CCR5 tropism result at screening, 7.6% had a dual/mixed-tropism result at the baseline visit 4 to 6 weeks later. This illustrates the background change from CCR5- to dual/mixed-tropism result over time in this treatment-experienced population, prior to a change in antiretroviral regimen or administration of a CCR5 co-receptor antagonist.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_53b0fcca-bd19-441d-9d1e-2044cd5ec"><BR>                           <caption>Table 12. Demographic and Baseline Characteristics of Subjects in Trials A4001027 and A4001028 </caption><BR>                           <col width="55%"/><BR>                           <col width="17%"/><BR>                           <col width="17%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule Toprule "/><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>SELZENTRY</paragraph><BR>                                    <paragraph>Twice Daily</paragraph><BR>                                    <paragraph>(N&#160;=&#160;426)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Placebo</paragraph><BR>                                    <paragraph>(N&#160;=&#160;209)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Age (years)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Mean (range)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>46.3 (21-73)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>45.7 (29-72)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Sex</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Male</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>382 (89.7%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>185 (88.5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Female</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>44 (10.3%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>24 (11.5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Race</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>White</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>363 (85.2%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>178 (85.2%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Black</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>51 (12.0%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>26 (12.4%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Other</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>12 (2.8%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>5 (2.4%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Region</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>U.S.</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>276 (64.8%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>135 (64.6%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Non-U.S.</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>150 (35.2%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>74 (35.4%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with previous enfuvirtide use</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>142 (33.3%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>62 (29.7%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with enfuvirtide as part of OBT</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>182 (42.7%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>91 (43.5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Baseline plasma HIV-1 RNA (log<sub>10</sub> copies/mL)</paragraph><BR>                                    <paragraph>Mean (range)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>4.85 (2.96-6.88)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>4.86 (3.46-7.07)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with screening</paragraph><BR>                                    <paragraph>viral load <content styleCode="underline">&gt;</content>100,000 copies/mL</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>179 (42.0%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>84 (40.2%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Baseline CD4+ cell count (cells/mm<sup>3</sup>) </paragraph><BR>                                    <paragraph>Median (range)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>167 (2-820)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>171 (1-675)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with baseline CD4+ cell count &#8804;200&#160;cells/mm<sup>3</sup>)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>250 (58.7%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>118 (56.5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Subjects with Overall Susceptibility Score (OSS):<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>0</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>57 (13.4%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>35 (16.7%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>1</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>136 (31.9%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>44 (21.1%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>2</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>104 (24.4%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>59 (28.2%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&#8805;3</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>125 (29.3%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>66 (31.6%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with enfuvirtide resistance mutations</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>90 (21.2%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>45 (21.5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Median number of resistance-associated:<sup>b</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                                 <td styleCode="Rrule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>PI mutations</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>10</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>10</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>NNRTI mutations</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>1</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>1</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>NRTI mutations</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>6</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>6</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           aOSS - Sum of active drugs in OBT based on combined information from genotypic and phenotypic testing. <BR>                        <BR>                           bResistance mutations based on IAS guidelines.1<BR>                        <BR>                        The Week 48 results for the pooled Trials A4001027 and A4001028 are shown in Table 13.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_793ceb08-5cc3-4601-924a-4f2b4d856"><BR>                           <caption>Table 13. Outcomes of Randomized Treatment at Week 48 Trials A4001027 and A4001028</caption><BR>                           <col width="70%"/><BR>                           <col width="15%"/><BR>                           <col width="12%"/><BR>                           <col width="18%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>Outcome</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>SELZENTRY</paragraph><BR>                                    <paragraph>Twice Daily</paragraph><BR>                                    <paragraph>(N&#160;=&#160;426)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Placebo</paragraph><BR>                                    <paragraph>(N&#160;=&#160;209)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Mean Difference</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Mean change from Baseline to Week 48 in HIV-1 RNA (log<sub>10</sub> copies/mL)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>-1.84</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>-0.78</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>-1.05 </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&lt;400&#160;copies/mL at Week 48</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>239 (56%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>47 (22%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>34% </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&lt;50&#160;copies/mL at Week 48</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>194 (46%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>35 (17%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>29% </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Discontinuations</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                                 <td styleCode="Rrule Botrule "/><BR>                                 <td styleCode="Rrule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Insufficient clinical response</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>97 (23%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>113 (54%)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Adverse events</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>19 (4%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>11 (5%)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Other</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>27 (6%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>18 (9%)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Subjects with treatment-emergent CDC Category C events </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>22 (5%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>16 (8%)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Deaths (during trial or within 28 days of last dose)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>9 (2%)<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>1 (0.5%)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           aOne additional subject died while receiving open-label therapy with SELZENTRY subsequent to discontinuing double-blind placebo due to insufficient response.<BR>                        After 48 weeks of therapy, the proportions of subjects with HIV-1 RNA <400 copies/mL receiving SELZENTRY compared with placebo were 56% and 22%, respectively. The mean changes in plasma HIV-1 RNA from baseline to Week 48 were –1.84 log10 copies/mL for subjects receiving SELZENTRY + OBT compared with –0.78 log10 copies/mL for subjects receiving OBT only. The mean increase in CD4+ cell count was higher on SELZENTRY twice daily + OBT (124 cells/mm3) than on placebo + OBT (60 cells/mm3).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Trial in Dual/Mixed-Tropic, Treatment-Experienced Subjects<BR>                     <BR>                        Trial A4001029 was an exploratory, randomized, double-blind, multicenter trial to determine the safety and efficacy of SELZENTRY in subjects infected with dual/mixed co-receptor tropic HIV-1. The inclusion/exclusion criteria were similar to those for Trials A4001027 and A4001028 above and the subjects were randomized in a 1:1:1 ratio to SELZENTRY once daily, SELZENTRY twice daily, or placebo. No increased risk of infection or HIV disease progression was observed in the subjects who received SELZENTRY. Use of SELZENTRY was not associated with a significant decrease in HIV-1 RNA compared with placebo in these subjects and no adverse effect on CD4+ cell count was noted.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Trial in Treatment-Naive Subjects<BR>                     <BR>                        Trial A4001026 is an ongoing, randomized, double-blind, multicenter trial in subjects infected with CCR5-tropic HIV-1 classified by the original TROFILE tropism assay. Subjects were required to have plasma HIV-1 RNA ≥2,000 copies/mL and could not have: 1) previously received any antiretroviral therapy for >14 days, 2) an active or recent opportunistic infection or a suspected primary HIV-1 infection, or 3) phenotypic or genotypic resistance to zidovudine, lamivudine, or efavirenz. Subjects were randomized in a 1:1:1 ratio to SELZENTRY 300 mg once daily, SELZENTRY 300 mg twice daily, or efavirenz 600 mg once daily, each in combination with zidovudine/lamivudine. The efficacy and safety of SELZENTRY are based on the comparison of SELZENTRY twice daily versus efavirenz. In a pre-planned interim analysis at 16 weeks, SELZENTRY 300 mg once daily failed to meet the pre-specified criteria for demonstrating non-inferiority and was discontinued.<BR>                        The demographic and baseline characteristics of the maraviroc and efavirenz treatment groups were comparable (Table 14). Subjects were stratified by screening HIV-1 RNA levels and by geographic region. The median CD4+ cell counts and mean HIV-1 RNA at baseline were similar for both treatment groups.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_72df88dd-fbc3-4b27-a61f-03b68e3f9"><BR>                           <caption>Table 14. Demographic and Baseline Characteristics of Subjects in Trial A4001026</caption><BR>                           <col width="30%"/><BR>                           <col width="44%"/><BR>                           <col width="41%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule Toprule "/><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>SELZENTRY 300&#160;mg Twice Daily + Zidovudine/Lamivudine</paragraph><BR>                                    <paragraph>(N&#160;=&#160;360)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Efavirenz 600&#160;mg Once Daily + Zidovudine/Lamivudine</paragraph><BR>                                    <paragraph>(N&#160;=&#160;361)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Age (years)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Mean</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>36.7</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>37.4</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Range</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>20-69</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>18-77</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Female, n%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>104 (29)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>102 (28)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Race, n%</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>White</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>204 (57)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>198 (55)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Black</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>123 (34)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>133 (37)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Asian</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6 (2)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5 (1)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Other</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>27 (8)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>25 (7)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Median (range) CD4+ cell count (cells/&#181;L)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>241 (5-1,422)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>254 (8-1,053)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Median (range) HIV-1 RNA (log<sub>10 </sub>copies/mL)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>4.9 ( 3-7)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>4.9 (3-7)</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The treatment outcomes at 96 weeks for Trial A4001026 are shown in Table 15. Treatment outcomes are based on reanalysis of the screening samples using a more sensitive tropism assay, Enhanced sensitivity TROFILE HIV tropism assay, which became available after the Week 48 analysis, approximately 15% of the subjects identified as CCR5-tropic in the original analysis had dual/mixed- or CXCR4-tropic virus. Screening with enhanced sensitivity version of the TROFILE tropism assay reduced the number of maraviroc virologic failures with CXCR4- or dual/mixed-tropic virus at failure to 12 compared with 24 when screening with the original TROFILE HIV tropism assay.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_77472d81-449d-45a2-a341-60cb3163a"><BR>                           <caption>Table 15: Trial Outcome (Snapshot) at Week 96 Using Enhanced Sensitivity Assay<sup>a</sup><BR>                           </caption><BR>                           <col width="36%"/><BR>                           <col width="50%"/><BR>                           <col width="30%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>Outcome at Week 96<sup>b</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>SELZENTRY 300&#160;mg Twice Daily + Zidovudine/Lamivudine</paragraph><BR>                                    <paragraph>N&#160;=&#160;311</paragraph><BR>                                    <paragraph>n (%)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Efavirenz 600 mg Once Daily +</paragraph><BR>                                    <paragraph>Zidovudine/Lamivudine</paragraph><BR>                                    <paragraph>N&#160;=&#160;303</paragraph><BR>                                    <paragraph>n (%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Virologic Responders: </paragraph><BR>                                    <paragraph>(HIV-1 RNA &lt;400&#160;copies/mL)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>199 (64)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>195 (64)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Virologic Failure:</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <list listType="unordered"><BR>                                       <item>Non-sustained HIV-1 RNA suppression</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>39 (13)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>22 (7)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <list listType="unordered"><BR>                                       <item>HIV-1 RNA never suppressed </item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>9 (3)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>1 (&lt;1)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Virologic Responders:</paragraph><BR>                                    <paragraph>(HIV-1 RNA &lt;50&#160;copies/mL)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>183 (59)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>190 (63)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Virologic Failure:</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "/><BR>                                 <td styleCode="Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <list listType="unordered"><BR>                                       <item>Non-sustained HIV-1 RNA suppression</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>43 (14)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>25 (8)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <list listType="unordered"><BR>                                       <item>HIV-1 RNA never suppressed</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>21 (7)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>3 (1)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Discontinuations due to:</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Lrule "/><BR>                                 <td styleCode="Rrule Lrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <list listType="unordered"><BR>                                       <item>Adverse events</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>19 (6)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>47 (16)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <list listType="unordered"><BR>                                       <item>Death</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>2 (1)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>2 (1)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <list listType="unordered"><BR>                                       <item>Other<sup>c</sup><BR>                                       </item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>43 (14)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>36 (12)</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           aThe total number of subjects (Ns) in Table 15 represents the subjects who had a CCR5-tropic virus in the reanalysis of screening samples using the more sensitive tropism assay. This reanalysis reclassified approximately 15% of subjects shown in Table 14 as having dual/mixed- or CXCR4-tropic virus. These numbers are different than those presented in Table 14 because the numbers in Table 14 reflect the subjects with CCR5-tropic virus according to the original tropism assay. <BR>                        <BR>                           bWeek 48 results: Virologic responders (<400): 228/311 (73%) in SELZENTRY, 219/303 (72%) in efavirenz;<BR>                        Virologic responders (<50): 213/311 (69 %) in SELZENTRY, 207/303 (68%) in efavirenz<BR>                        <BR>                           cOther reasons for discontinuation include lost to follow-up, withdrawn, protocol violation, and other.<BR>                        The median increase from baseline in CD4+ cell counts at Week 96 was 184 cells/mm3 for the arm receiving SELZENTRY compared with 155 cells/mm3 for the efavirenz arm. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>